ArticleFrontiers in medicine2025
Prediction of TP53 mutations across female reproductive system pan-cancers using deep multimodal PET/CT radiogenomics.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: TP53 mutations play a critical role in the clinical management and prognostic evaluation of gynecologic malignancies such as cervical, endometrial, and ovarian cancers. With the advancement of radiomics and deep learning technologies, noninvasive AI models based on medical imaging have become important tools for assessing TP53 mutation status. Methods: This study retrospectively analyzed 259 patients with cervical, endometrial, or ovarian cancer who underwent PET/CT before treatment. Radiomics features from tumors and brown adipose tissue (BAT) were extracted, and a Transformer-based model was developed to predict TP53 mutation by integrating imaging and clinical data. The model was trained with five-fold cross-validation, and clustering analysis was performed on deep features to explore their correlation with TP53 status. Results: Radiomic features from tumor CT images, tumor PET images, brown adipose tissue CT images, and brown adipose tissue PET images were all found to be associated with TP53 mutation status in gynecological tumors. On the test set, the accuracy of the tumor CT radiomic model was 0.7931, the tumor PET radiomic model achieved an accuracy of 0.8276, the brown adipose tissue CT radiomic model had an accuracy of 0.7241, and the brown adipose tissue PET radiomic model reached an accuracy of 0.7931. The combined model achieved an accuracy of 0.8620 on the test set, and after automatic annotation using nn-UNet, the combined model's accuracy was 0.8000. Unsupervised clustering of the deep features extracted by the combined model showed that the image clustering patterns were significantly correlated with TP53 mutation status ( Conclusion: This study demonstrates that radiomic features from tumor and brown adipose tissue CT and PET images are closely associated with TP53 mutation status in gynecological tumors. This study constructed a cross-cancer TP53 model. The combined model constructed based on multi-modal imaging effectively captures TP53-related imaging phenotypes across different cancer types, and these phenotypic patterns show a significant correlation with TP53 mutation status.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.